期刊
TRANSPLANT INFECTIOUS DISEASE
卷 23, 期 1, 页码 -出版社
WILEY
DOI: 10.1111/tid.13464
关键词
concentration; lung transplant; respiratory syncytial virus; ribavirin; ribavirin triphosphate
Ribavirin may improve outcomes in lung transplant patients with RSV; however, further studies are needed to understand its pharmacokinetics in different respiratory compartments to guide clinical use for respiratory viruses.
Respiratory syncytial virus (RSV) is responsible for significant morbidity and mortality in the lung transplant population. Oral and aerosolized ribavirin may improve outcomes in lung transplant patients with RSV; however, data relating ribavirin concentrations in plasma and intracellular ribavirin triphosphate (iRTP) concentrations in blood and bronchoalveolar lavage (BAL) fluid cells with efficacy and safety are lacking. We describe ribavirin and iRTP concentrations within various compartments in two adult lung transplant recipients with RSV who were sampled throughout successful treatment courses with oral and inhaled ribavirin. In patient 1, iRTP BAL concentrations decreased by 45% over 3 days after changing inhaled ribavirin to oral (6.32 to 3.43 pmol/10(6)cells). In patient 2, iRTP BAL concentrations were 103 pmol/10(6)cells after 5 days of oral followed by 5 days of inhaled ribavirin. Further study is needed to describe ribavirin pharmacokinetics in the respiratory compartment to inform clinical use of ribavirin for respiratory viruses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据